Log in  First Connection?

SchizophreniaArchives

Analyzing the direct medical cost of schizophrenia in Hospital Pulau Pinang, Malaysia
Schizophrenia
 1 min.

 Published on 19/05/2026 |  Original article (Full-text)  | Fuad Fadhel Alotaibi et al. | Expert Review of Pharmacoeconomics & Outcomes Research 2026; aop:10.1080/14737167.2026.2659625

Schizophrenia (SCZ) is a major public health concern that places a significant economic burden on healthcare systems. This study assessed the direct medical costs of SCZ and examined cost drivers at Hospital Pulau Pinang (HPP), Malaysia. To estimate and compare direct medical costs for SCZ patients across...

The Cancer Screening Disparity among Women With Schizophrenia by Co-occurring Chronic Physical Illness Status: A Nationwide Cohort Study in Taiwan
Schizophrenia
 1 min.

 Published on 12/05/2026 |  Original article (Full-text)  | Ching-Ching Claire Lin et al. | Schizophrenia bulletin. Volume 52(2).

To investigate the association between co-occurring chronic physical illnesses (CPIs) and breast and cervical cancer screening rates among women with schizophrenia in Taiwan. Study Methods: This retrospective cohort study analyzed Taiwan National Health Insurance claims data from 2017 to 2019. The sample...

Neurophysiological Resting-State Markers of Catatonia in Schizophrenia and Mood Disorders
Schizophrenia
 1 min.

 Published on 05/05/2026 |  Original article (Full-text)  | Mylène Moyal et al. | Schizophrenia bulletin. Volume 52(2).

Identifying reliable diagnostic biomarkers in catatonia remains a key challenge to improve early intervention and reduce morbidity and mortality. Since its pathophysiology may involve cortical dysconnectivity, electroencephalography (EEG) could provide accessible disease-associated measures, such as...

Pharmacogenomic and inflammatory determinants of antipsychotic-induced extrapyramidal toxicity in Egyptian patients with schizophrenia
Schizophrenia
 1 min.

 Published on 28/04/2026 |  Original article (Full-text)  | Asmaa Mohamed Sayed Ahmed et al. | Expert opinion on drug metabolism & toxicology 2026; 22(3): 233-242

Extrapyramidal symptoms (EPS) are side effects of antipsychotic therapy, and genetic and inflammatory mechanisms may contribute to EPS risk. This study investigated the associations among ABCC2 (rs4148396) gene polymorphisms, serum interleukin-6 (IL-6) levels, and risperidone-induced EPS among patients...